CASI Pharmaceuticals Reports Q3 2024 Results: Strategic Focus on Organ Transplant and Autoimmune Therapies

November 16, 2024 Catherine Williams - Chief Editor Health

CASI Pharmaceuticals Reports Third Quarter 2024 Results

CASI Pharmaceuticals, Inc., a biopharmaceutical company, announced its financial results for the third quarter of 2024. The company specializes in developing innovative drugs for organ transplant rejection and autoimmune diseases.

Key Highlights:

  • Strategic Focus: CASI is refining its development strategies for treating organ transplant rejection and autoimmune diseases. The Chinese National Medical Products Administration has approved a clinical trial for CID-103 to treat chronic Immune Thrombocytopenia (ITP). This aligns with a global study previously approved by the US FDA.

  • Financial Overview:
    • Total Revenue: $7.8 million, a 12% decrease from the third quarter of 2023 but a 96% increase compared to the second quarter of 2024.
    • Costs of Revenue: $3.7 million, slightly up from $3.6 million in Q3 2023 and up from $1.9 million in Q2 2024.
    • Research and Development Expenses: $1.5 million, down from $2.4 million in Q3 2023 due to prior year amortization expenses.
    • General and Administrative Expenses: $5.7 million, compared to $5.5 million in the same period last year.
    • Selling and Marketing Expenses: $4.9 million, increasing from $2.5 million in Q3 2023.
    • Net Loss: $8.4 million, compared to a loss of $4.5 million in the previous year.

Company Background:
CASI Pharmaceuticals aims to develop drugs for unmet medical needs, focusing on hematology oncology and autoimmune diseases. It operates globally, with a strong presence in China.

Contact Information:
For more details, contact Rui Zhang at CASI Pharmaceuticals, Inc. at 240.864.2643 or via email at ir@casipharmaceuticals.com.

End of Report